These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Cost-effectiveness of sensor-augmented pump therapy in two different patient populations with type 1 diabetes in Italy. Nicolucci A; Rossi MC; D'Ostilio D; Delbaere A; de Portu S; Roze S Nutr Metab Cardiovasc Dis; 2018 Jul; 28(7):707-715. PubMed ID: 29753586 [TBL] [Abstract][Full Text] [Related]
3. Continuous subcutaneous insulin infusion vs modern multiple injection regimens in type 1 diabetes: an updated meta-analysis of randomized clinical trials. Pala L; Dicembrini I; Mannucci E Acta Diabetol; 2019 Sep; 56(9):973-980. PubMed ID: 30945047 [TBL] [Abstract][Full Text] [Related]
4. Does the timing of insulin pump therapy initiation after type 1 diabetes onset have an impact on glycemic control? Shalitin S; Lahav-Ritte T; Lebenthal Y; Devries L; Phillip M Diabetes Technol Ther; 2012 May; 14(5):389-97. PubMed ID: 22283639 [TBL] [Abstract][Full Text] [Related]
5. Effects of sensor-augmented pump therapy on glycemic variability in well-controlled type 1 diabetes in the STAR 3 study. Buse JB; Kudva YC; Battelino T; Davis SN; Shin J; Welsh JB Diabetes Technol Ther; 2012 Jul; 14(7):644-7. PubMed ID: 22524549 [TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and meta-analysis. Yeh HC; Brown TT; Maruthur N; Ranasinghe P; Berger Z; Suh YD; Wilson LM; Haberl EB; Brick J; Bass EB; Golden SH Ann Intern Med; 2012 Sep; 157(5):336-47. PubMed ID: 22777524 [TBL] [Abstract][Full Text] [Related]
7. Incremental value of continuous glucose monitoring when starting pump therapy in patients with poorly controlled type 1 diabetes: the RealTrend study. Raccah D; Sulmont V; Reznik Y; Guerci B; Renard E; Hanaire H; Jeandidier N; Nicolino M Diabetes Care; 2009 Dec; 32(12):2245-50. PubMed ID: 19767384 [TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of Sensor-Augmented Insulin Pump Therapy Versus Continuous Insulin Infusion in Patients with Type 1 Diabetes in Turkey. Roze S; Smith-Palmer J; de Portu S; Özdemir Saltik AZ; Akgül T; Deyneli O Diabetes Technol Ther; 2019 Dec; 21(12):727-735. PubMed ID: 31509715 [No Abstract] [Full Text] [Related]
9. Comparison of Different Treatment Modalities for Type 1 Diabetes, Including Sensor-Augmented Insulin Regimens, in 52 Weeks of Follow-Up: A COMISAIR Study. Šoupal J; Petruželková L; Flekač M; Pelcl T; Matoulek M; Daňková M; Škrha J; Svačina Š; Prázný M Diabetes Technol Ther; 2016 Sep; 18(9):532-8. PubMed ID: 27482825 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of the Adherence to Continuous Glucose Monitoring in the Management of Type 1 Diabetes Patients on Sensor-Augmented Pump Therapy: The SENLOCOR Study. Picard S; Hanaire H; Baillot-Rudoni S; Gilbert-Bonnemaison E; Not D; Reznik Y; Guerci B Diabetes Technol Ther; 2016 Mar; 18(3):127-35. PubMed ID: 26950530 [TBL] [Abstract][Full Text] [Related]
11. Long-term health economic benefits of sensor-augmented pump therapy vs continuous subcutaneous insulin infusion alone in type 1 diabetes: a U.K. perspective. Roze S; Smith-Palmer J; Valentine WJ; Cook M; Jethwa M; de Portu S; Pickup JC J Med Econ; 2016; 19(3):236-42. PubMed ID: 26510389 [TBL] [Abstract][Full Text] [Related]
12. Effectiveness of sensor-augmented pump therapy in children and adolescents with type 1 diabetes in the STAR 3 study. Slover RH; Welsh JB; Criego A; Weinzimer SA; Willi SM; Wood MA; Tamborlane WV Pediatr Diabetes; 2012 Feb; 13(1):6-11. PubMed ID: 21722284 [TBL] [Abstract][Full Text] [Related]
13. Metabolic control after years of completing a clinical trial on sensor-augmented pump therapy. Quirós C; Giménez M; Orois A; Conget I Endocrinol Nutr; 2015 Nov; 62(9):447-50. PubMed ID: 26521155 [TBL] [Abstract][Full Text] [Related]